Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Pathstone Holdings LLC

Pathstone Holdings LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 69,392 shares of the medical research company's stock after selling 6,164 shares during the period. Pathstone Holdings LLC's holdings in Thermo Fisher Scientific were worth $36,120,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Stonegate Investment Group LLC grew its stake in Thermo Fisher Scientific by 0.3% in the fourth quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock valued at $3,531,000 after acquiring an additional 18 shares during the period. Semus Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after buying an additional 18 shares during the last quarter. Eagle Rock Investment Company LLC grew its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock valued at $3,882,000 after purchasing an additional 19 shares during the period. KRS Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after purchasing an additional 20 shares during the last quarter. Finally, Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TMO. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Raymond James reaffirmed an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. StockNews.com lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $607.43.

Thermo Fisher Scientific Trading Down 0.9%

NYSE:TMO opened at $428.88 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $401.75 and a one year high of $627.88. The company's 50-day simple moving average is $460.85 and its 200 day simple moving average is $513.11. The firm has a market capitalization of $161.90 billion, a P/E ratio of 25.95, a PEG ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the company earned $5.11 EPS. The firm's revenue for the quarter was up .2% on a year-over-year basis. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a $0.43 dividend. The ex-dividend date was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's payout ratio is 10.09%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 over the last 90 days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.